Pneumocystis jirovecii
pneumocystis jiroveciipneumocystis pneumoniaPCP pneumoniaHIV opportunistic infectionsAIDS defining illnessCD4 less than 200ART opportunistic infectionimmunocompromised pneumoniasteroid induced PCPtransplant PCPTMP SMX treatmentcotrimoxazole PCPPCP prophylaxisdapsone prophylaxispentamidineclindamycin primaquineground glass opacitiesinterstitial pneumoniaβ-D glucanLDH elevatedBAL diagnosisARDSpneumothorax PCPnon HIV PCPsevere PCPmoderate PCPPCP managementPCP case scenariosNEET PG medicineMBBS final medicine
Below is your **complete, concise-but-exhaustive medical note on *Pneumocystis jirovecii* (PCP) pneumonia**, following your preferred pattern:
✔️ Definition
✔️ Pathophysiology
✔️ Risk factors
✔️ Clinical features
✔️ Investigations
✔️ Differential diagnoses
✔️ Management (stepwise)
✔️ Full drug details (indications, MoA, dosing, PK, side effects, contraindications, monitoring, counselling)
✔️ Prophylaxis
---
# **PNEUMOCYSTIS JIROVECII (PCP) – COMPLETE NOTE**
## **1. DEFINITION**
Pneumocystis jirovecii pneumonia (PCP) is a **severe opportunistic fungal pneumonia** caused by *P. jirovecii*, seen mainly in **HIV patients with CD4 <200**, transplant patients, long-term steroid users, and other immunocompromised states.
Although fungal, PCP behaves like an **atypical interstitial pneumonia**.
---
## **2. PATHOPHYSIOLOGY**
* *P. jirovecii* colonizes alveoli → multiplies in immunosuppressed hosts.
* Causes **diffuse alveolar damage** and **protein-rich foamy intra-alveolar exudate**.
* Leads to:
* Impaired gas exchange
* Severe **hypoxemia**
* ↑ A–a gradient
* Interstitial inflammation (predominantly plasma cells, lymphocytes).
* Surfactant dysfunction → ↓ lung compliance.
---
## **3. RISK FACTORS**
### **HIV-related**
* **CD4 <200 cells/µL**
* High viral load
* Prior PCP infection
* Not on ART
### **Non-HIV**
* Prolonged steroids (>20 mg/day prednisone ≥4 weeks)
* Solid organ transplant
* Hematologic malignancies
* Chemotherapy
* TNF-α inhibitor therapy
* Chronic lung disease
* Severe malnutrition
* Post-COVID immunosuppression
---
## **4. CLINICAL FEATURES**
### **Symptoms**
* **Subacute fever**
* **Progressive dyspnea** (HIV: weeks; non-HIV: days)
* **Dry nonproductive cough**
* Pleuritic chest pain
* Fatigue, weight loss
### **Signs**
* Tachypnea, tachycardia
* **Hypoxemia with exertion first**
* Bibasal fine crackles
* Cyanosis (late)
### **Severe disease marker**
* **PaO₂ <70 mmHg** or **A–a gradient >35 mmHg**
---
## **5. INVESTIGATIONS**
### **1. Blood tests**
* ↑ LDH (often >500 IU/L) – nonspecific but supportive
* β-D-glucan positive in many cases
* ABG: ↓ PaO₂, ↑ A–a gradient
### **2. Imaging**
#### **Chest X-ray**
* **Bilateral diffuse interstitial / ground-glass opacities** (“bat-wing” pattern)
* No effusion typically
#### **HRCT chest**
* **Ground-glass opacities**, septal thickening (crazy-paving)
### **3. Microbiology**
* Induced sputum (40–60% sensitive)
* BAL (90–99% sensitive) – gold standard
* Stains: silver stain, Giemsa
* PCR highly sensitive
* DFA staining
### **4. Special Tests**
* Serum LDH high
* β-D-glucan elevated
---
## **6. DIFFERENTIAL DIAGNOSES**
* CMV pneumonia
* Bacterial pneumonia (esp. atypical)
* Viral pneumonias (COVID, influenza)
* Tuberculosis
* Hypersensitivity pneumonitis
* ARDS
* Alveolar proteinosis
* Drug-induced pneumonitis (amiodarone, MTX)
---
# **7. MANAGEMENT (STEPWISE)**
## **A. Assess severity**
* **Mild–moderate** → PaO₂ ≥70
* **Moderate–severe** → PaO₂ <70 or A–a gradient >35
---
## **B. First-line treatment**
# **1. TMP–SMX (Co-trimoxazole)**
**Indication:** First line for all severities
**Mechanism of action:**
* TMP: inhibits dihydrofolate reductase
* SMX: inhibits dihydropteroate synthase
→ Combined **folate synthesis inhibition** in organism
### **Adult Dosing**
* **TMP 15–20 mg/kg/day + SMX 75–100 mg/kg/day** IV or PO divided q6–8h for **21 days** (HIV)
* **Non-HIV:** 14 days may be adequate
### **Pharmacokinetics**
* Good lung penetration
* Renal elimination
* Adjust dose in renal impairment
### **Side Effects**
Common:
* Nausea, vomiting
* Rash
* Hyperkalemia
* Hyponatremia
* AKI
* Elevated LFTs
Serious:
* **Stevens–Johnson syndrome (SJS)**
* **Hemolysis in G6PD deficiency**
* Bone marrow suppression
* Aseptic meningitis
### **Contraindications**
* Sulfa allergy
* Severe hepatic failure
* Significant marrow suppression
### **Drug interactions**
* Warfarin ↑ INR
* ACEI/ARBs + TMP → severe hyperkalemia
* Methotrexate → marrow toxicity
### **Monitoring**
* CBC
* Creatinine
* Electrolytes (esp. K⁺, Na⁺)
* LFTs
### **Patient counselling**
* Drink adequate water
* Report rash immediately
* Avoid OTC NSAIDs
* Expect gradual improvement over days
---
## **C. Adjunctive corticosteroids**
🚨 Only in **moderate–severe PCP** (PaO₂ <70 or A–a >35)
### **Prednisone regimen:**
* Day 1–5: **40 mg PO BID**
* Day 6–10: **40 mg PO daily**
* Day 11–21: **20 mg PO daily**
OR
IV methylprednisolone (75% equivalent dose)
---
## **D. Alternatives to TMP–SMX**
### **1. Pentamidine (IV)**
Indication: severe PCP when TMP-SMX contraindicated
MoA: inhibits DNA/RNA/protein synthesis
Dose: **4 mg/kg/day IV**
PK: renal excretion, accumulates in tissues
Side effects:
* Nephrotoxicity
* Hypoglycemia → hyperglycemia
* Pancreatitis
* Arrhythmias
* Hypotension
* Electrolyte abnormalities
Monitoring: glucose, renal function, ECG
---
### **2. Atovaquone (PO)**
For mild–moderate PCP
MoA: inhibits mitochondrial electron transport
Dose: **750 mg PO BID with fatty meal** × 21 days
Side effects: rash, GI upset, ↑ LFTs
---
### **3. Clindamycin + Primaquine**
Indication: Mild–moderate when TMP–SMX not tolerated
MoA: protein synthesis inhibition + oxidative damage
Dose:
* Clindamycin 600–900 mg IV TID
* Primaquine 15–30 mg PO daily
Side effects:
* Hemolysis in G6PD deficiency
* Rash
* Diarrhea
---
### **4. Dapsone + TMP**, **Dapsone + Trimethoprim**
Avoid in G6PD deficiency
Side effects: methemoglobinemia, hemolysis
---
# **8. PROPHYLAXIS (VERY IMPORTANT)**
### **Indications for primary prophylaxis**
* HIV: **CD4 <200** or oropharyngeal candidiasis
* Non-HIV: prolonged steroids, transplant, chemo
### **First-line prophylactic agent**
## **TMP–SMX 1 DS tablet daily OR 1 SS daily**
Alternatives:
* Dapsone
* Atovaquone
* Aerosolized pentamidine
Stop prophylaxis when:
* HIV: CD4 >200 for >3 months on ART
---
# **9. COMPLICATIONS**
* Respiratory failure
* Pneumothorax (subpleural cysts rupture)
* ARDS
* Death if untreated
---
# **10. KEY EXAM POINTS**
* LDH ↑ is supportive, not diagnostic
* HIV: subacute, non-HIV: severe + rapid
* Steroids improve mortality when PaO₂ <70
* TMP–SMX remains the **gold standard**
* Never give primaquine or dapsone without **G6PD testing**
---
If you want, I can also provide:
✅ **10–30 case scenarios**
✅ **Hard MCQs (HTML + CSS + JS in one file)**
✅ **Differential diagnosis scenarios**
Just tell me how many you want.
Below are **25 high-yield, exam-style, real-life case scenarios of *Pneumocystis jirovecii* pneumonia (PCP)**.
Each case includes:
✔ Presentation
✔ Key findings
✔ Diagnosis triggers
✔ Management steps
If you want, I can also generate **hard MCQs**, **HTML/JS quiz files**, or **expanded management pathways**.
---
# **📘 25 CASE SCENARIOS — PNEUMOCYSTIS JIROVECII (PCP)**
---
## **CASE 1 — Classic HIV PCP**
A 32-year-old male with newly diagnosed HIV (CD4 = 84) presents with **progressive dyspnea × 3 weeks**, dry cough, fever.
SpO₂ drops from 94% to 82% on minimal exertion.
CXR: **Bilateral diffuse ground-glass opacities**.
LDH: 560 U/L.
ABG: PaO₂ 60 mmHg.
**Diagnosis:** Moderate–severe PCP
**Management:** IV TMP–SMX + prednisone taper.
---
## **CASE 2 — Sudden deterioration**
A patient on day 4 of TMP–SMX for PCP suddenly develops acute pleuritic pain and hypoxia.
CXR: **Large right pneumothorax**.
**Complication:** PCP-related pneumothorax (due to subpleural cyst rupture).
**Management:** Chest tube + continue PCP treatment.
---
## **CASE 3 — Non-HIV, rapid onset**
A 60-year-old man on **prednisone 40 mg/day for 2 months** (interstitial lung disease) develops acute dyspnea × 3 days.
Very hypoxic.
CXR: diffuse interstitial infiltrates.
**Diagnosis:** Non-HIV PCP
**Management:** IV TMP–SMX; early steroids (PaO₂ <70).
---
## **CASE 4 — HIV patient on ART default**
A 28-year-old defaulted ART for 1 year.
Now presents with weight loss + fever + cough.
CD4 = 36.
β-D-glucan positive.
**Diagnosis:** PCP
**Management:** TMP–SMX; start ART after **2 weeks** (to avoid IRIS).
---
## **CASE 5 — Prophylaxis failure**
A 44-year-old HIV patient on **dapsone prophylaxis** develops PCP.
G6PD was never checked.
**Diagnosis:** Breakthrough PCP (dapsone failure due to improper absorption or resistance).
**Management:** Switch to TMP–SMX; check G6PD.
---
## **CASE 6 — Transplant patient**
A kidney-transplant recipient on tacrolimus + prednisone presents with progressive dyspnea, dry cough, fever.
CT: **ground-glass infiltrates**.
**Diagnosis:** PCP in transplant recipient
**Management:** IV TMP–SMX + careful renal dosing + steroids.
---
## **CASE 7 — Cancer chemotherapy**
A 52-year-old woman receiving rituximab for lymphoma presents with fever, tachypnea, dry cough × 5 days.
HRCT: diffuse GGO; LDH elevated.
BAL PCR positive.
**Management:** TMP–SMX + prednisone.
---
## **CASE 8 — Post-COVID immune suppression**
A man received high-dose steroids for COVID ARDS.
Now, 6 weeks later: fever, breathlessness.
CT: ground-glass infiltrates.
**Diagnosis:** Steroid-induced PCP
**Management:** TMP–SMX ± steroids.
---
## **CASE 9 — Mild PCP**
A 33-year-old HIV+ woman, CD4 = 170, has mild dry cough and fever.
PaO₂ = 76 mmHg.
**Management:** Oral TMP–SMX (mild); no steroids.
---
## **CASE 10 — Severe PCP with respiratory failure**
HIV+ man arrives in ED with RR 40/min, cyanosis.
PaO₂ = 48 mmHg.
**Diagnosis:** Severe PCP
**Management:** ICU care + IV TMP–SMX + IV methylprednisolone.
---
## **CASE 11 — Patient allergic to sulfa**
HIV+ woman with known SJS to sulfa drugs presents with PCP.
**Management:**
* Clindamycin + primaquine
* Or IV pentamidine if severe
* Test G6PD before primaquine.
---
## **CASE 12 — PCP in poorly nourished patient**
A 50-year-old alcoholic with severe malnutrition develops dyspnea × 10 days.
BAL positive.
**Management:** TMP–SMX; screen for electrolyte disturbances.
---
## **CASE 13 — β-D-glucan positive but CXR normal**
Early PCP: LDH high, β-D-glucan positive, but normal X-ray.
HRCT shows patchy ground-glass changes.
**Diagnosis:** Early PCP
**Management:** TMP–SMX.
---
## **CASE 14 — PCP in pregnancy**
HIV+ pregnant woman with CD4 = 90 presents with worsening breathlessness.
CT avoided; X-ray shows diffuse infiltrates.
**Management:** TMP–SMX (benefits outweigh risks); steroids if indicated; folinic acid.
---
## **CASE 15 — Relapse after stopping prophylaxis early**
HIV patient stopped TMP–SMX prophylaxis when CD4 became 210 for only 6 weeks.
Now presents with PCP.
**Cause:** Prophylaxis was stopped too early.
**Management:** Full treatment + restart prophylaxis until CD4 >200 for **≥3 months**.
---
## **CASE 16 — Hyperkalemia due to therapy**
A patient on high-dose TMP–SMX for PCP develops K⁺ = 6.1.
**Cause:** TMP inhibits renal potassium excretion.
**Management:** Treat hyperkalemia; adjust TMP–SMX dose.
---
## **CASE 17 — AKI during therapy**
Creatinine rises to 2.4 mg/dL on TMP–SMX.
**Management:**
* Dose adjust
* Monitor electrolytes
* Ensure hydration
* Consider alternative if worsening.
---
## **CASE 18 — PCP vs CMV pneumonia confusion**
Transplant patient has fever and diffuse infiltrates.
PCP stains negative; CMV PCR very high.
**Diagnosis:** CMV pneumonia (PCP mimic).
**Management:** Ganciclovir.
---
## **CASE 19 — PCP in patient on TNF-α inhibitor**
A patient on infliximab for rheumatoid arthritis develops fever, progressive breathlessness.
CT: interstitial GGO.
**Diagnosis:** Immunosuppression-related PCP
**Management:** TMP–SMX.
---
## **CASE 20 — PCP with severe hyponatremia**
A patient develops Na = 121 due to TMP–SMX + SIADH-like effect.
**Management:** Correct sodium + continue treatment with caution.
---
## **CASE 21 — PCP + Pneumothorax + ARDS overlap**
Severely ill PCP patient on ventilator suddenly has worsening hypoxia.
CXR: bilateral infiltrates + small pneumothorax.
**Management:**
* Ventilation with low tidal volume
* Chest tube if needed
* Continue PCP therapy.
---
## **CASE 22 — PCP in untreated HIV found incidentally**
A homeless patient with chronic cough is brought in.
CXR done for TB screening shows diffuse opacities.
BAL reveals PCP.
**Management:** TMP–SMX + ART initiation after 2 weeks.
---
## **CASE 23 — PCP in obesity-hypoventilation syndrome**
Obese immunosuppressed patient presents with confusion and dyspnea.
ABG: Severe hypoxemia + hypercapnia.
**Management:**
* NIV/CPAP
* TMP–SMX
* Steroids
* Slow oxygen escalation to avoid CO₂ retention.
---
## **CASE 24 — PCP in patient with hematologic malignancy**
AML patient receiving chemotherapy becomes febrile and dyspneic.
CT: diffuse bilateral GGO.
BAL PCR: positive for *P. jirovecii*.
**Management:** IV TMP–SMX; consider pentamidine if neutropenia.
---
## **CASE 25 — PCP diagnosed only on HRCT**
CXR normal.
HRCT: classic ground-glass with septal thickening (“crazy-paving”).
BAL unavailable.
**Diagnosis:** Radiologic PCP
**Management:** TMP–SMX.
---
If you want, I can now create:
✅ **20–30 Hard MCQs**
✅ **HTML + CSS + JS interactive quiz file**
✅ **Differential diagnosis case bundle**
Just tell me how many.